ZYME Profile
Zymeworks Inc. (ZYME) is a clinical-stage biopharmaceutical company that develops multifunctional therapeutics for the treatment of cancer, autoimmune and inflammatory diseases. The company's proprietary platform, Azymetric™, enables the design and engineering of bispecific antibodies and antibody-drug conjugates (ADCs). Zymeworks has several programs in clinical development, including ZW25 and ZW49, which are bispecific antibodies targeting HER2-expressing cancers, and ZW33, an ADC targeting solid tumors.
In addition to its internal pipeline, Zymeworks has partnerships with several pharmaceutical companies, including Merck, GlaxoSmithKline, and Daiichi Sankyo, for the development of Azymetric™-based therapeutics.
Zymeworks was founded in 2003 and is headquartered in Vancouver, Canada. The company went public in 2017 and is traded on the New York Stock Exchange under the ticker symbol ZYME.
|
